A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Michel Seymour(University of Leeds), Alfred Oliver(World Cancer Research Fund International), John Wagstaff(Maastricht University Medical Centre), Susan D. Richman(University of Leeds), Ian Chau(Royal Marsden NHS Foundation Trust), Simon Gollins(Velindre Cancer Centre), Catherine Lowe(University of Hertfordshire), Vicky Napp(University of Leeds), Sarah Brown(University of Leeds), Mark Hill(Maidstone Hospital), John Bridgewater(University College London Hospitals NHS Foundation Trust), Tim Maughan(University of Liverpool), Sun Myint(Clatterbridge Cancer Centre NHS Foundation Trust), D R Blake(Royal Victoria Infirmary), Sarah Slater(Barts Health NHS Trust), Nick Maisey(National Health Service), Helen Marshall(University of Leeds), Stephen J. Gwyther(East Surrey Hospital), Jonathan Wadsley(Weston Park Cancer Centre)
Cited by 24
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k